Ocular Surface Distribution and Pharmacokinetics of a Novel Ophthalmic 1% Azithromycin Formulation

被引:51
作者
Akpek, Esen Karamursel [2 ]
Vittitow, Jason [1 ]
Verhoeven, Rozemarijn S. [1 ]
Brubaker, Kurt [1 ]
Amar, Thierry [3 ]
Powell, Kendall D. [4 ]
Boyer, Jose L. [1 ]
Crean, Christopher [1 ]
机构
[1] Inspire Pharmaceut Inc, Durham, NC 27703 USA
[2] Johns Hopkins Univ Hosp, Wilmer Eye Inst, Ocular Surface Dis & Dry Eye Clin, Baltimore, MD 21287 USA
[3] Iris Pharma, La Gaude, France
[4] Enthalpy Analyt Inc, Durham, NC USA
关键词
RESPIRATORY-TRACT INFECTIONS; BACTERIAL CONJUNCTIVITIS; PHARMACODYNAMICS; ANTIBIOTICS; CP-62,993; MACROLIDE; RELEASE; SINGLE; SITES; CELLS;
D O I
10.1089/jop.2009.0026
中图分类号
R77 [眼科学];
学科分类号
100212 [眼科学];
摘要
Purpose: To investigate the ocular distribution of 1% azithromycin ophthalmic solution and the effect of polycarbophil-based mucoadhesive formulation on ocular tissue levels of azithromycin after single and multiple topical administrations in the rabbit eye. Methods: Rabbits were treated with either a single administration of 1% azithromycin solution with or without polycarbophil, or with multiple administrations of 1% azithromycin solution in polycarbophil. Drug concentrations were measured using LC/MS/MS. Conjunctiva, cornea, aqueous humor, and tear samples were analyzed over a period of 144 h after a single administration of azithromycin with or without polycarbophil. Eyelid, conjunctiva, cornea, aqueous humor, and tear samples were collected over a period of 288 h during and after multiple administrations of azithromycin. Results: Azithromycin was rapidly absorbed and distributed in the ocular tissues, reaching within 5 min, concentrations of 10,539 mu g/mL in tear film, 108 mu g/g in conjunctiva, and 40 mu g/g in the cornea. The drug demonstrated tissue-specific half-lives of 15, 63, and 67 h, respectively. Following multiple administrations, the drug gradually accumulated. The polycarbophil formulation increased the bioavailability of the drug, producing peak concentrations that were between 5- and 12-fold higher than those without polycarbophil. Azithromycin also distributed rapidly in the eyelids, reaching peak concentrations of 180 mu g/g at the end of the 7-day treatment, and was eliminated with a half-life of 125 h. Six days after treatment was discontinued, eyelid levels of azithromycin were above 40 mu g/g. Conclusions: Sustained and high concentrations were encountered with 7-day approved administration of 1% azithromycin formulation (AzaSite (R), Inspire Pharmaceuticals, Inc., Durham, NC) within all ocular surface tissues, particularly the lids. Many ocular surface disorders involving the tear film, eyelids, and adnexal structures are associated with chronic, low-grade bacterial infection and may potentially lead to decreased vision secondary to corneal scarring. Various topical antibiotic and steroid combinations with or without oral tetracyclines are commonly used with variable clinical response and known potential side effects. The clinical relevance of this study is unknown; however, the long-lasting antibacterial and additional anti-inflammatory properties of topical azithromycin might offer an effective alternative treatment option and should be explored further in clinical studies.
引用
收藏
页码:433 / 439
页数:7
相关论文
共 22 条
[1]
Clinical cure of bacterial conjunctivitis with azithromycin 1%: Vehicle-controlled, double-masked clinical trial [J].
Abelson, Mark B. ;
Heller, Warren ;
Shapiro, Aron M. ;
Si, Erwin ;
Hsu, Peng ;
Bowman, Lyle M. .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2008, 145 (06) :959-965
[2]
Ocular pharmacokinetic study following single and multiple azithromycin administrations in pigmented rabbits [J].
Amar, Thierry ;
Caillaud, Thierry ;
Elena, Pierre-Paul .
CURRENT EYE RESEARCH, 2008, 33 (02) :149-158
[4]
Erythromycin, clarithromycin, and azithromycin: Are the differences real? [J].
Amsden, GW .
CLINICAL THERAPEUTICS, 1996, 18 (01) :56-72
[5]
BALDWIN DR, 1990, EUR RESPIR J, V3, P886
[6]
Drusano GL, 1997, J CHEMOTHERAPY, V9, P38
[7]
Friedlaender MH, 2007, CLIN OPHTHALMOL, V1, P3
[8]
INTRACELLULAR ACCUMULATION OF AZITHROMYCIN BY CULTURED HUMAN FIBROBLASTS [J].
GLADUE, RP ;
SNIDER, ME .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (06) :1056-1060
[9]
INVITRO AND INVIVO UPTAKE OF AZITHROMYCIN (CP-62,993) BY PHAGOCYTIC-CELLS - POSSIBLE MECHANISM OF DELIVERY AND RELEASE AT SITES OF INFECTION [J].
GLADUE, RP ;
BRIGHT, GM ;
ISAACSON, RE ;
NEWBORG, MF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (03) :277-282
[10]
Ianaro A, 2000, J PHARMACOL EXP THER, V292, P156